Connect with us

Cannabis

Leading Brand to Participate in 2nd Annual Cannabis Conference

Published

on

cannabis conference

Khiron is a vertically integrated leading name in cannabis industry having its basic operations in South America. The company has just announced that it will be taking part in the Cowen 2nd Annual Boston Cannabis Conference. The conference will take place on November 12, Tuesday, 2019 to November 13, 2019 in Boston, Massachusetts.

The Intercontinental Hotel will be hosting the whole event where there will be fresh updates about all institutional investors in the market. These institutional investors will bring information regarding already existing as well as upcoming products in the market.

This will be a quite informative event targeted at bringing out all new investors at one platform and paving a way for future investments. That initiative will help the market to grow and become better in all cases.

There will be 15 high-interest panel discussions that will cover all topics that include cannabinoids in different aspects. Payments, retail, sustainability, legislation and regulation will be the highlights of the entire conference.

Furthermore, all American cannabis brands as well as international markets will be discussed by high think tanks and the senior management belonging to the cannabis market.

At the conference, Khiron Chief Executive Officer Alvaro Torres will also be present at the conference. They will be available for individualized and pre-booked meetings after the conference. In addition to that, Mr. Torres will be joining the panel discussion of the conference that will be covering the international cannabis markets.

Khiron Life Sciences Corporation is placed at the leading position in the cannabis retail market in the region of South America. Khiron has its operations in the region and is a fully licensed and registered name in Colombia for cultivating purposes. The company produces, locally distributes, and even exports medical cannabis.

THC – tetrahydrocannabinol, and CBD – cannabidiol, both components are available in the strains of medical cannabis they produce and sell in the market.

The organization has a best in class compliance for regulation for cannabis, and has the first approved cannabinoid domestic products for cosmetic purposes in the area of Colombia. Moreover, it is helping the facility testing for getting registered through an official license for its cannabis derived products for commercial usage.

The company has a regional strategy and moves with a patient oriented aim. It combines the global scientific expertise, innovation in agriculture, product name in brand and entrance idea in the market.

Brand loyalty and an educational experience also comes under the name of the targets this company wants to achieve. Moreover, alleviation of problems like chronic pain, anxiety, and other mental health problems in the region are also among the goals of this company.

Alvaro Torres has an experienced executive team under his company who is responsible for carrying out all major and minor technicalities and address tot the issues related to the company.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Cannabis

Researchers Are Working On A New Cannabis Saliva Test For Impaired Drivers

Published

on

Drivers who are intoxicated with alcohol, while driving, are often subjected to roadside stops, in the United States, where they are asked to take breathalyzer tests and would further have to go through stiff penalties if the alcohol content in their blood exceeds the legal limitations. However, there is no current test that exists, for cannabis intoxication.

Scientists have now reported that they are another step closer to the invention of a convenient saliva test that will measure the cannabis levels at roadside stops. American Chemical Society (ACS) SciMeeetings online platform, will be where the researchers will be presenting their results.

According to Shalini Prasad, Ph.D., who led the study, people usually tend to think that drunk driving is worse than driving after smoking cannabis and consider the latter to be relatively “safer”. However, she further explained how both substances can cause similar effects in the body such as slowed reaction time, diminished alertness, and reduced self-awareness.

Tetrahydrocannabinol  (THC) is the psychoactive compound in cannabis and constitutes impairment. However, the safe levels of THC in blood, unlike alcohol, have not been well characterized. According to Prasad, despite it being an emerging field, 1 to 15 nanograms of THC per milliliter of blood, is suggested by the preliminary clinical reports, to be considered a level of impairment.

The law enforcement agencies are focusing on how to keep the roads safe from high drivers, as more U.S states continue the decriminalization of cannabis. The blood tests for THC are time-consuming and invasive, despite the accuracy. Along with that, this is not a convenient test for many police officers to perform skillfully at roadside stops. Some researchers are working on a cannabis test that would be similar to a breathalyzer for alcohol, to measure THC levels in the breath.

However, according to Prasad, extensive and error-prone data processing would be required to filter out the effects of other compounds as the levels of THC are low in the breath. Consequently, focusing on the close correlation between saliva and blood, Prasad and colleagues aimed at the development of a saliva test for THC that would be simple, quick and accurate.

THC sensor strips and an electronic reader were engineered by researchers at the University of Texas at Dallas. The sensor strips contained two electrodes and were coated with an antibody. The antibody binds with THC and isolates it from other compounds in the saliva. According to Prasad, the antibody is used, to focus only on the needle in the haystack.

The researchers performed the test by adding a tiny drop of human saliva that was spiked with THC, on the strip. The strip was then inserted into the electronic reader, which further applied a specific voltage. The electric current changed due to the occurrence of the polarization between the interacting antibody and the THC surfaces, shortly after the THC attached to the antibody. THC concentration would then be traceable after the conversion of data by the e-reader.

However, for THC levels ranging from 100 picograms per milliliter to 100 nanograms per milliliter, the device held accuracy. According to Prasad, this prototype was the first to be able to report both low and high concentrations of THC, with high sensitivity and specificity. Furthermore, the test requires less than five minutes to perform and complete.

Due to legal issues regarding cannabis in Texas, THC spiked saliva is what researchers are working with rather than actual cannabis smokers. However, law enforcement agencies and researchers from other states where cannabis is legalized, are interested in collaboration.

Additionally, lawmakers and regulatory groups have shown interest to develop effective laws by using the data generated by the device.

Continue Reading

Cannabis

Cannabis And The Mental Health – The Risks Involved

Published

on

The cannabis plant consists of over 500 identified chemical constituents, out of which over 100 are cannabinoids. Cannabinoids interact with the endocannabinoid system – a naturally occurring communication network that exists in our brains and bodies. Varying amounts and combinations of the dosages of cannabis, can, in turn, affect several physiological and psychological processes in different ways such as – gastrointestinal function, appetite, pain, memory, movement, immunity, inflammation, and mental health are all included.

The complexity of cannabis, however, is what makes it a potential medication for numerous illnesses. The concern is the gap that exists between the hype about cannabis, and the research with evidence supporting the hype. The concern holds a lot of relevance to mental health, where the effectiveness of cannabis as a treatment for a variety of psychiatric conditions, such as depression, anxiety, post-traumatic stress, psychosis, and addiction, is touted.

However, the reality of cannabis is that it cannot be held on the extremes of being either strictly helpful or strictly harmful. Instead, discussion regarding the potential benefits and harms of cannabis are encouraged, but with careful and nuanced consideration of science, with an addition of a humble attitude.

The science regarding the role of the endocannabinoid system in mood regulation is very clear with respect to depression. The use of cannabis or particular cannabinoids, in the treatment of depressive disorders, has had no support from any randomized controlled trials yet. On the contrary, the existing scientific data is mixed and tilts towards the idea of the worsening and development of depressive symptoms, by the ingestion of cannabis plant material. Although these findings are not satisfying, they aren’t straightforward either.

Delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two best-known examples of cannabinoids found in the cannabis plant. Generally, the production of anxiety and psychotic features has been shown by THC, especially at higher doses. Meanwhile, production of anxiolytic and antipsychotic effects have been shown by CBD

However, a person’s increased or decreased anxiety or psychotic symptoms after ingesting cannabis can be affected by several other variables. This could include

  • Potency levels – Any presence of other cannabis-related chemicals
  • The amount of cannabis used
  • The frequency of use by the patient
  • Any past experience with cannabis
  • The patient’s likelihood to develop and/or experience psychiatric symptoms

There is added confusion regarding the relationship between cannabis and addiction. According to scientific literature, a substantial minority of users could hold the possibility of cannabis addiction – euphoric effects of THC are expected to be held somewhat responsible for the addictive potential. This includes the possibility of cannabis addiction in one in ten people, which still holds the representation of a large number of people.

A replacement to opioids by cannabis is encouraged if the goal of the treatment would be the reduction of harm. However, cannabis treatment for other substance addictions is not the most ideal option. Addiction involves more complications than cannabis itself. That may be the reason that cannabis-based medicines cannot be the solution to the treatment of addiction, even while it may play a helpful role in it. Solutions of addiction may continue to be multipronged as the causes of it are multifaceted.

In conclusion, the person’s motive for cannabis use matters. Temporary relief and avoidance from uncomfortable thoughts and emotions may be provided by the use of cannabis but psychiatric and psychological treatments focus on the skills and coping mechanisms to confront the difficult thoughts and emotions. Research shows, use of cannabis with this motive could ultimately lead to difficulties with mental health symptoms, and addiction. Positive and negative reinforcement could be caused by mind-altering substances such as high THC cannabis products.

 

Continue Reading

Cannabis

Glaucoma and Cannabis : What Opthalmologists Have To Say

Published

on

Myths can stay around for a long time. One of them was about Cannabis being a potential treatment for glaucoma patients. Glaucoma is a complex eye condition that involves the damage of the optic nerve over time, initially reducing peripheral vision and ultimately leading to blindness. The higher than normal eye pressure (intraocular pressure or IOP) is one of the major causes of optic nerve damage.

With the legalization of medical and recreational cannabis use in more U.S. states and Canada, researchers have been studying the use of cannabis as possible treatments for various health conditions. Although research from the 1970s and 1980s has shown a detectable drop in intraocular pressure for three to four hours, after the consumption of cannabis – by smoking, or by the ingestion of TH in the form of pills or injection, treatment for glaucoma would require control of eye pressure for a complete 24 hours.

Studies show that ingestion of about 18 to 20 mg of THC, six to eight times daily, is required for the reduction and maintenance of intraocular pressure by 3 to 5 mm Hg. This could also include significant negative effects on mood, mental clarity, and lung health (if smoked). Driving, operation of machinery, or engagement in various common activities would be prohibited. Additionally, the amount of cannabis needed to be consumed every three to four hours makes it cost-prohibitive for a significant number of patients.

Comparatively, alcohol has moderate intraocular pressure-lowering effects for an hour after consumption. However, the consumption of alcohol would never be recommended by doctors as a treatment for glaucoma.

Is THC Effective or Reliable as a Treatment for Glaucoma?

THC eye drops, pills and cigarettes have been studied, and the results aren’t positive. Burning and irritated eyes were caused by eye drops, with no decrease in eye pressure. Similarly, no decrease in eye pressure was recorded, after the use of sublingual THC compounds either. Meanwhile, use of THC-containing pills and/or cigarettes was stopped by patients after 9 months, due to the side effects.

With further research about glaucoma, scientists have concluded that the high intraocular pressure in the fluid at the front of the eye, is not the sole cause of the optic nerve damage. Further evidence shows that another cause could be the reduced blood flow in the optic nerve. While cannabis may lower eye pressure, it also lowers the patient’s blood pressure. Thus, the potential of cannabis to lower blood pressure effectively cancels out its ability to lower intraocular pressure.

What About CBD?

Currently available cannabis and cannabis-derived compounds – like CBD is not a sufficient treatment for any eye condition, including glaucoma. Cannabis is not a practical treatment to maintain lowered eye pressure for 24 hours, in order to treat glaucoma.

CBD has gained a lot of attention and scrutiny in the last few years. Although CBD is a derivative of cannabis as well, it doesn’t cause any mood-altering effects. However, current research does not support the use of CBD as an effective treatment for glaucoma. On the contrary, a recent study has shown that an increase in IOP may be caused by the CBD, making glaucoma worse.

The Future of Cannabis For Glaucoma Treatment

Currently, ophthalmologists say that the only way to control glaucoma and control vision is to lower the patient’s intraocular pressure. Depending on the type of glaucoma and severity, ophthalmologists can use medications such as prescription eye drops or surgery, as a form of treatment for glaucoma.

Furthermore, cannabis or any other cannabis products are NOT RECOMMENDED for the treatment of glaucoma, by the American Academy of Opthalmology, along with the agreement of the American Glaucoma Society and the Canadian Opthalmological Society.

Continue Reading

Trending